They would have needed to raise serious VC money and spend enormous amounts of time on development.

FORBES: Taking the Pulse of the Cloud

Second, the public markets loved biotech, so it was easy to raise money at attractive prices and provide exits for VC investors even when these companies were at relatively early stages of development.

FORBES: Virtual R&D: Drug Development In The New Millennium